151 related articles for article (PubMed ID: 1707083)
21. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract][Full Text] [Related]
23. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
[TBL] [Abstract][Full Text] [Related]
24. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR
Prog Clin Biol Res; 1988; 260():101-10. PubMed ID: 2966402
[No Abstract] [Full Text] [Related]
25. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate].
Lo Cigno M; Montanari F; Bercovich E; Soli M; Emili E; Dal Pozzo C; Platè L; Bianchi D
Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):29-36. PubMed ID: 2469127
[TBL] [Abstract][Full Text] [Related]
26. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
27. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
Wallentin L; Varenhorst E
J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
[TBL] [Abstract][Full Text] [Related]
28. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
[No Abstract] [Full Text] [Related]
29. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
30. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
Sekido N; Kawai K; Akaza H; Koiso K
Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
[TBL] [Abstract][Full Text] [Related]
31. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
32. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
Tauveron I; Hermabessière J
Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
[No Abstract] [Full Text] [Related]
33. Decrease of serum testosterone by cyproterone acetate accompanied by an unexpected increase of calcitonin secretion capacity.
Mulder H; Eland D; Hackeng WH; Schopman W
J Urol; 1987 Aug; 138(2):324-5. PubMed ID: 2955132
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
35. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
36. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of megestrol acetate as monotherapy in disseminated prostatic carcinoma].
Gallo Rolania FJ
Arch Esp Urol; 1998 Mar; 51(2):151-3. PubMed ID: 9586312
[TBL] [Abstract][Full Text] [Related]
38. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
40. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]